NEOPLASMS

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This pilot study tested a device called NaviFUS that uses focused ultrasound to temporarily open the blood-brain barrier, combined with the drug bevacizumab (Avastin), in 6 patients with recurrent glioblastoma (a type of brain cancer). The goal was to see if the combination is sa…

This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth to treat advanced solid tumors that had not responded to standard treatments. Fifty-nine adults participated, taking the drugs on a 3-days-on, 4-days-off schedule in 21-day cycles. The main goal w…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or returned after other treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body…

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This early-stage study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the safety of the drug and how the body processes it. Thi…

This early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…

This early-phase study tested a new immunotherapy drug (BI 754091) alone or combined with another drug (BI 754111) in 146 Asian patients with advanced solid tumors like stomach, liver, and lung cancer. The main goals were to find safe doses and check for side effects. Researchers…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received…

This early-phase study tested a new treatment called RD13-02, which uses a patient's own immune cells modified to attack cancer cells with a specific marker (CD7). It included 2 people with blood cancers that had come back or stopped responding to standard treatments. The main go…

This study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…

This study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…

This early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This early-phase study tested an experimental drug called JNJ-70218902 in 82 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by redirecting the body's T cells to attack cancer cells. The main goals were to find the safest dose …

This early-stage study tested a new drug called JNJ-64619178 in 114 people with advanced cancers, including lymphoma, solid tumors, and myelodysplastic syndromes. The main goal was to find the safest dose and check for side effects. The drug works by blocking a protein that helps…

This study tested a device called PointCheck that uses light to check for severe neutropenia (low white blood cells) in cancer patients without needing a blood sample. Researchers enrolled 81 adults with blood or breast cancers who were receiving chemotherapy. The main goal was t…

This study tested a special pad worn for 4-6 hours to collect cells shed from the uterus. Researchers wanted to see if the pad could gather enough cells to tell the difference between normal tissue, precancerous changes, and cancer. 80 women scheduled for surgery wore the pad, an…

This study tested whether a high-resolution PET-MRI scan using a prostate-specific tracer (18F-PSMA) can find cancers that standard MRI might miss. 62 men with prostate cancer considering focal therapy or surgery received both scans, and results were checked with biopsies. The go…

This study tested a financial navigation program to help cancer patients in rural and non-rural North Carolina deal with the high costs of care. 258 adults with cancer and significant financial distress took part. The program aimed to reduce financial toxicity and improve quality…

This study tested whether a mix of in-person and online physiotherapy sessions is practical for children aged 4–17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which used fun activities like jumping and balancing. The goal was to see if fam…

This study tested whether a mobile app could help cancer patients recognize and report treatment side effects more effectively. 222 adults receiving chemotherapy or radiation therapy used the app to track symptoms and share them with their doctors. The goal was to improve patient…

This study looked at whether a program called expressive helping—where people write or record their feelings—is helpful for Chinese-speaking cancer patients and survivors. About 60 adults with any type of cancer took part. The goal was to see if the program was easy to use and if…

This study looked at how cancer treatment changes taste and smell, and whether that makes it harder for patients to follow a Mediterranean diet. 116 patients completed questionnaires and taste tests before and after 9 weeks of treatment. The goal was to understand what affects ea…

This study looked at whether giving antibiotics before a kidney drainage procedure (called percutaneous nephrostomy) prevents urinary tract infections in cancer patients whose urinary tract is blocked by a tumor. Researchers reviewed records of 320 cancer patients who had the pro…

This study tested a mobile program designed to help young adult cancer survivors (ages 18-39) eat healthier and be more physically active. 72 survivors joined the pilot trial to see if the program was easy to use and well-liked. The goal was to gather information on how to best s…

This study looked at 330 older adults (65+) who had cancer surgery to see if low albumin levels before surgery led to more complications. Researchers compared patients with low albumin to those with normal levels, tracking problems like infections, hospital stay length, and ICU n…

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 adults with advanced or metastatic cancer. The goal was to find safe doses for each drug combination to use in future, larger studies. The…

This study looked at over 200,000 adults with obesity and type 2 diabetes to see if the type of diabetes medication they took before a cancer diagnosis affected their survival and complications after cancer. Researchers compared GLP-1 receptor agonists (like Ozempic) with other d…

This study looked at how often cancer patients who are also at risk for bleeding develop dangerous blood clots. Researchers followed 700 hospitalized cancer patients to track clot rates and understand how to better manage these situations. The goal was to gather information to im…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study looked at 33 patients who had both cancer and a bleeding disorder called immune thrombocytopenia (ITP). The goal was to see if cancer cells trick the immune system into attacking the body's own platelets. Researchers found that treating the cancer often helped the ITP …

This study tested whether machine learning can analyze facial expressions and voice recordings to measure pain in people with cancer. 83 participants, aged 12 and older, recorded short videos at clinic visits and at home over about 3 months. The goal was to see if this technology…